Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis I
Conditions
Mucopolysaccharidosis I, Hurler Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome
Trial Timeline
Dec 1, 2005 → Oct 1, 2006
NCT ID
NCT00258011About Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) is a phase 3 stage product being developed by Sanofi for Mucopolysaccharidosis I. The current trial status is completed. This product is registered under clinical trial identifier NCT00258011. Target conditions include Mucopolysaccharidosis I, Hurler Syndrome, Hurler-Scheie Syndrome.
What happened to similar drugs?
5 of 14 similar drugs in Mucopolysaccharidosis I were approved
Approved (5) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00258011 | Phase 3 | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis I